Recommended screening and preventive practices for long-term survivors after hematopoietic cell transplantation: joint recommendations of the European Group for Blood and Marrow Transplantation, Center for International Blood and Marrow Transplant Research, and the American Society for Blood and Marrow Transplantation (EBMT/CIBMTR/ASBMT).
More than 40,000 hematopoietic cell transplants (HCTs) are performed worldwide each year. With improvements in transplant technology, larger numbers of transplant recipients survive free of the disease for which they were transplanted. However, there are late complications that can cause substantial morbidity. Many survivors are no longer under the care of transplant centers and many community health-care providers may be unfamiliar with health matters relevant to HCT. The Center for International Blood and Marrow Transplant Research (CIBMTR), European Group for Blood and Marrow Transplantation (EBMT), and American Society for Blood and Marrow Transplantation (ASBMT) have developed these recommendations to offer care providers suggested screening and prevention practices for autologous and allogeneic HCT survivors.
Rizzo
J D
JD
Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA.
Wingard
J R
JR
Tichelli
A
A
Lee
S J
SJ
Van Lint
M T
MT
Burns
L J
LJ
Davies
S M
SM
Ferrara
J L M
JL
Socié
G
G
D003695:Delivery of Health Care / Q000592:standards; D018572:Disease-Free Survival; D005060:Europe; D005260:Female; D006282:Health Personnel / Q000592:standards; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods / Q000401:mortality / Q000592:standards*; D006801:Humans; D008297:Male; D012955:Societies, Medical; D014481:United States